WO2010033980A3 - 4-azaindole bisphosphonates - Google Patents

4-azaindole bisphosphonates Download PDF

Info

Publication number
WO2010033980A3
WO2010033980A3 PCT/US2009/057819 US2009057819W WO2010033980A3 WO 2010033980 A3 WO2010033980 A3 WO 2010033980A3 US 2009057819 W US2009057819 W US 2009057819W WO 2010033980 A3 WO2010033980 A3 WO 2010033980A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
azaindole
bisphosphonates
methods
disorders
Prior art date
Application number
PCT/US2009/057819
Other languages
French (fr)
Other versions
WO2010033980A2 (en
Inventor
Frank Hallock Ebetino
Adam Mazur
Mark Walden Lundy
Robert Graham Goodwin Russell
Original Assignee
Isis Innovation Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Innovation Ltd. filed Critical Isis Innovation Ltd.
Publication of WO2010033980A2 publication Critical patent/WO2010033980A2/en
Publication of WO2010033980A3 publication Critical patent/WO2010033980A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Novel 4-azaindole bisphosphonate compounds are disclosed, as well as methods of preparing the compounds, pharmaceutical compositions including the compounds, and administration of the compounds in methods of treating abnormal calcium and phosphate metabolism, including bone and joint diseases and other disorders.
PCT/US2009/057819 2008-09-22 2009-09-22 4-azaindole bisphosphonates WO2010033980A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9907608P 2008-09-22 2008-09-22
US61/099,076 2008-09-22

Publications (2)

Publication Number Publication Date
WO2010033980A2 WO2010033980A2 (en) 2010-03-25
WO2010033980A3 true WO2010033980A3 (en) 2010-07-01

Family

ID=42040197

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/057819 WO2010033980A2 (en) 2008-09-22 2009-09-22 4-azaindole bisphosphonates

Country Status (1)

Country Link
WO (1) WO2010033980A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5850842B2 (en) 2009-10-26 2016-02-03 ワーナー・チルコット・カンパニー・エルエルシー Bisphosphonate compounds for treating bone metabolic disorders
WO2011147038A1 (en) 2010-05-28 2011-12-01 The Royal Institution For The Advancement Of Learning/Mcgill University Heterocyclyl-pyridinyl-based biphosphonic acid, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof
US9290526B2 (en) 2010-05-28 2016-03-22 The Royal Institution For The Advancement Of Learning/Mcgill University Heterocyclyl-pyridinyl-based biphosphonic acid, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof
GB201317363D0 (en) 2013-10-01 2013-11-13 Eisai Ltd Novel compounds
WO2019076269A1 (en) 2017-10-16 2019-04-25 清华大学 Mevalonic acid pathway inhibitor and pharmaceutical composition thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4990503A (en) * 1988-08-12 1991-02-05 Yamanouchi Pharmaceutical Co., Ltd. Heterocyclic bisphosphonic acid derivatives

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4990503A (en) * 1988-08-12 1991-02-05 Yamanouchi Pharmaceutical Co., Ltd. Heterocyclic bisphosphonic acid derivatives

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
FULFARO, F. ET AL.: "The role of bisphosphonates in the treatment of painful metastatic bone disease: a review of phase III trials", PAIN., vol. 78, 1998, pages 157 - 169 *
LECERCLE, D ET AL.: "Phosphine-catalyzed alpha-P-addition on activated alkynes: new route to P-C-P backbones", ORGANIC LETTERS., vol. 8, no. 19, 2006, pages 4282 - 4285 *
SANDERS, J. M. ET AL.: "3-D QSAR investigations of the inhibition of Leishmanina major Farnesyl Pyrophophate Synthesis by Bisphosphonates", JOURNAL OF MEDICINAL CHEMISTRY, vol. 46, no. 24, 2003, pages 5171 - 5183 *
SZABO, C. ET AL.: "An investigation of bone resorption and Dictyostelium discoideum Growth Inhibition by Bisphosphonate Drugs", JOURNAL OF MEDICINAL CHEMISTRY, vol. 45, no. 14, 2002, pages 2894 - 2903 *

Also Published As

Publication number Publication date
WO2010033980A2 (en) 2010-03-25

Similar Documents

Publication Publication Date Title
WO2010033978A3 (en) IMIDAZO[1,2-α ]PYRIDINYL BISPHOSPHONATES
MX2018015635A (en) Compositions and methods for modulation of smn2 splicing in a subject.
PH12015502708A1 (en) Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis
EA025746B9 (en) Compounds and their use as beta site app cleaving enzyme (bace) inhibitors
WO2012078593A3 (en) Lysophosphatidic acid receptor antagonists and their use in the treatment fibrosis
MX2010005931A (en) Prodrugs of tetrahydrocannabinol, compositions comprising prodrugs of tetrahydrocannabinol and methods of using the same.
WO2013009701A3 (en) Metal bisphosphonate nanoparticles for anti-cancer therapy and imaging and for treating bone disorders
WO2011041694A3 (en) Compounds as lysophosphatidic acid receptor antagonists
WO2011017350A3 (en) Compounds as lysophosphatidic acid receptor antagonists
WO2011041461A3 (en) Polycyclic compounds as lysophosphatidic acid receptor antagonists
WO2006055329A3 (en) Dental fillers including a phosphorus-containing surface treatment
MY160907A (en) Sphingosine 1 phosphate receptor modulators and methods of chiral synthesis
WO2011023367A3 (en) Bisphosphonate-prodrugs
WO2009135190A3 (en) Therapeutic calcium phosphate particles and methods of making and using same
WO2011092469A8 (en) 1-(5-tert-butyl-2-phenyl-2h-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy
WO2007146085A3 (en) Creatine phosphate prodrugs, compositions and uses thereof
WO2008097924A3 (en) Pharmaceutical compositions comprising dextromethorphan analogs for the treatment of neurological disorders
MY169497A (en) Selective heterocyclic sphingosine 1 phosphate receptor modulators
NZ600947A (en) Fused Aromatic Difluoromethanephosphonates as Protein Tyrosine Phosphatase 1B (PTP-1B) Inhibitors
MX2012000166A (en) Phosphorus containing quinazoline compounds and methods of use.
MY156302A (en) COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF ß-AMYLOID DISEASES AND SYNUCLEINOPATHIES
WO2012158550A3 (en) Selective heterocyclic sphingosine 1 phosphate receptor modulators
WO2010033980A3 (en) 4-azaindole bisphosphonates
WO2010033981A3 (en) 5-azaindole bisphosphonates
MX364680B (en) Solid composition for oral administration containing ibandronic acid or a pharmaceutically acceptable salt thereof and vitamin d.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09815378

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09815378

Country of ref document: EP

Kind code of ref document: A2